Azelaic acid
Azelaic Acid, Azelex, Finacea (azelaic acid) is a small molecule pharmaceutical. Azelaic acid was first approved as Azelex on 1995-09-13. It is used to treat acne vulgaris and rosacea in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Azelaic acid, Azelex, Finacea (discontinued: Azelaic acid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azelaic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AZELEX | Almirall | N-020428 RX | 1995-09-13 | 1 products, RLD, RS |
| FINACEA | LEO Pharma | N-021470 RX | 2002-12-24 | 1 products, RLD, RS |
| FINACEA | LEO Pharma | N-207071 RX | 2015-07-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 10% azelaic acid acne cream | unapproved drug other | 2024-09-29 |
| 15% azelaic acid acne cream | unapproved drug other | 2024-09-29 |
| anubismed | OTC monograph final | 2023-09-05 |
| azelaic acid | ANDA | 2022-05-30 |
| azelaic acid 15% / niacinamide 4% | unapproved drug other | 2019-04-23 |
| azelaic acid gel | ANDA | 2024-04-30 |
| azelex | New Drug Application | 2024-03-04 |
| biboya azelaic acid tea tree acne cream | C200263 | 2024-08-15 |
| finacea | New Drug Application | 2023-02-06 |
| finacea foam | New Drug Application | 2020-12-08 |
Show 1 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acne vulgaris | EFO_0003894 | D000152 | L70 |
| rosacea | — | D012393 | L71 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rosacea | D012393 | — | L71 | 3 | 3 | 8 | 6 | 3 | 22 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 1 | 3 | 1 | 4 | 1 | 9 |
| Melanosis | D008548 | HP_0001480 | L81.1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Skin manifestations | D012877 | — | — | — | — | — | 2 | — | 2 |
| Hyperpigmentation | D017495 | HP_0000953 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erythema | D004890 | HP_0010783 | L53.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | — | — | — | 2 |
| Seborrheic dermatitis | D012628 | HP_0001051 | L21 | — | 1 | — | — | — | 1 |
| Perioral dermatitis | D019557 | EFO_1001305 | L71.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 1 | — | — | — | — | 1 |
| Alopecia | D000505 | HP_0002293 | L64 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin abnormalities | D012868 | HP_0000951 | Q82.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Azelaic acid |
| INN | azelaic acid |
| Description | Nonanedioic acid is an alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups. It has a role as an antibacterial agent, an antineoplastic agent, a dermatologic drug and a plant metabolite. It is a dicarboxylic fatty acid and an alpha,omega-dicarboxylic acid. It is a conjugate acid of an azelaate(2-) and an azelaate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCCCCCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 123-99-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1238 |
| ChEBI ID | 48131 |
| PubChem CID | 2266 |
| DrugBank | DB00548 |
| UNII ID | F2VW3D43YT (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Azelaic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,661 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,347 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use